Trinity Biotech (TRIB) Cost of Revenue (2009 - 2024)

Trinity Biotech (TRIB) has reported Cost of Revenue for 16 consecutive years, with $11.0 million the latest figure, recorded in Q4 2024.

• Quarterly Cost of Revenue rose 23.91% year-over-year to $11.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $40.1 million (up 7.31% YoY) and the FY2025 annual result came in at $26.9 million, down 32.95% from the prior year.
• Cost of Revenue improved to $11.0 million in Q4 2024 per TRIB's latest filing, from $9.8 million in the prior quarter.
• Over the last five years, Cost of Revenue for TRIB reached as high as $17.1 million in Q4 2020 and fell as low as $8.9 million in Q4 2023.
• A 5-year average of $11.6 million and a median of $10.4 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2021 — Cost of Revenue jumped 61.87% — and 2022, when it tumbled 33.98%.
• Year by year, Cost of Revenue stood at $17.1 million in 2020, then decreased by 28.19% to $12.3 million in 2021, then declined by 15.76% to $10.4 million in 2022, then retreated by 14.39% to $8.9 million in 2023, then advanced by 23.91% to $11.0 million in 2024.
• According to Business Quant data, Cost of Revenue over the past three periods registered $11.0 million, $9.8 million, and $10.1 million for Q4 2024, Q3 2024, and Q2 2024 respectively.